Wedbush Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $52
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $46 to $52.
Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $46 to $52.